Skip to main content

Table 1 Protocol Schedule and Activities

From: Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Procedures common to both protocols

Screening (Visit 1)

Study period

Day 1 (Baseline Visit 2)

Days 7, 30, 60, 90, 120, 150 (Visits 3, 4, 5, 6, 7, 8)

Day 180 (Visit 9)

Signed Informed Consent

X

   

Inclusion/Exclusion Reviewed

X

X

X

 

Medical/Surgical/Medication History

X

   

Physical Examination

X

   

Vital Signs

X

X

X

X

Heighta, Weight, BMI

X

  

X

Clinical Assessment for Knee Pain & Swelling

X

X

X

X

Knee Flexion Range of Motion

 

X

X

X

X-ray examination

X

   

WOMAC Score

X

X

X

X

VAS Scale

X

X

X

X

LFI Score

X

X

X

X

Clinical Laboratory Tests (hematology, chemistry, urinalysis)

X

  

X

Urine Pregnancy Test (if applicable)

X

 

X

X

Serum biomarker analysis-COMP

 

X

 

X

Randomization Number Assigned

 

X

  

Investigational Product Administration

 

X

  

Dispense Subject Diary

 

X

X

 

Collect/Review Subject Diary

  

X

X

Provide Directions for Concomitant Medication and Rescue Medication Use

X

X

X

 

Dispense New Investigational Product

 

X

X

 

Review Product Accountability

  

X

X

Assess use of Concomitant Medications

 

X

X

X

Adverse Events Assessed

 

X

X

X

Procedures Confined to Protocol 003348

    

Synovial fluid biomarker—MMP-3 and IL-6

 

X

 

X

Serum biomarker analysis—CRP

 

X

 

X

  1. aHeight was measured only at Visit 1